Your browser doesn't support javascript.
loading
Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial.
Birkeland, Eline; Gharagozlian, Sedegheh; Gulseth, Hanne L; Birkeland, Kåre I; Hartmann, Bolette; Holst, Jens J; Holst, René; Aas, Anne-Marie.
Affiliation
  • Birkeland E; Section of Nutrition and Dietetics, Division of Medicine, Department of Clinical Service, Oslo University Hospital, Oslo, Norway.
  • Gharagozlian S; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Gulseth HL; Section of Nutrition and Dietetics, Division of Medicine, Department of Clinical Service, Oslo University Hospital, Oslo, Norway.
  • Birkeland KI; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.
  • Hartmann B; Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.
  • Holst JJ; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Holst R; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
  • Aas AM; Department of Biomedical Sciences and NNF Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Diabet Med ; 38(10): e14657, 2021 10.
Article in En | MEDLINE | ID: mdl-34297363
AIMS: We aimed to investigate the effect of prebiotic inulin-type fructans (ITF) versus a control supplement on postprandial levels of glucagon-like peptide-1 and -2 (GLP-1 and -2), glucose and insulin in people with type 2 diabetes. METHODS: Adult men and women with type 2 diabetes were randomised in a double-blind, placebo-controlled crossover study. The study participants received 16 g/d ITF and 16 g/d control supplement (maltodextrin) for 6 weeks each in two phases separated by a 4-week washout. A standardised mixed-meal test was performed before and after each intake period. The primary end point was changes in the GLP-1 response, and secondary end points were GLP-2, glucose and insulin responses. Data were analysed using mixed-model analysis. RESULTS: A total of 29 participants were included in the study. Differences between and within the two treatments in estimated area under the curves were not significant. Yet, the predicted means for meal-induced GLP-1 response in plasma showed a 4.8% decline after the prebiotic treatment and an 8.6% increase after the control treatment (difference in changes between the treatments, p < 0.001). Fasting or postprandial glucose, insulin or GLP-2 levels were not changed. CONCLUSIONS: Our findings do not support that ITF improve incretin responses or glucose regulations in this population. Clinicaltrials.gov (NCT02569684).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Glucose / Postprandial Period / Glucagon-Like Peptide 1 / Glucagon-Like Peptide 2 / Prebiotics / Fructans / Inulin Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabet Med Journal subject: ENDOCRINOLOGIA Year: 2021 Type: Article Affiliation country: Norway

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Glucose / Postprandial Period / Glucagon-Like Peptide 1 / Glucagon-Like Peptide 2 / Prebiotics / Fructans / Inulin Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabet Med Journal subject: ENDOCRINOLOGIA Year: 2021 Type: Article Affiliation country: Norway